Kenneth Craig and Kenneth Pattullo of Begbies Traynor, the Joint Liquidators of XstalBio Limited (in Liquidation) (the “Company” or “XstalBio”) have appointed Metis Partners to support the marketing and sale of the intellectual property (“IP”) assets belonging to the Company.
IP ASSET HIGHLIGHTS
- CentuRecon – Industry-First Drug Reconstitution Technology
- High Profile Industry Partnerships
- Industry Recognition
- International Patent Filing Coverage
- Attractive Commercialisation Opportunity in the Pharma and Medical Device Spaces
- Significant Development Opportunity in the Biologics Space
Metis Partners is offering an excellent opportunity to purchase the IP assets behind a leading bioformulation and drug delivery company with proprietary technologies that are applied to the delivery of bio-pharmaceuticals to patients in the most efficient manner.
All offers and requests for more information should be submitted by email directly to Aylin Dzhafer at email@example.com. The deadline for offers has been set at Wednesday, 23rd November 2016 at noon.
XstalBio was established as a spin out from the University of Strathclyde to develop drug powder formulations for biologic drugs and vaccines. XstalBio’s proprietary technologies were designed to solve a wide range of bioformulation and delivery problems, and the Company has successfully formulated over 40 active pharmaceutical ingredients (APIs), working with many of the world’s top pharmaceutical and biotechnology companies.
Market segments who may be interested in this opportunity include, but are not limited to, the pharmaceutical, biologics, and the medical device sectors. The Technology also has excellent potential in the centrifuge manufacturing and drug delivery markets.
CENTURECON TECHNOLOGY OVERVIEW
The Company has launched CentuRecon, a patent-backed reconstitution technology that has the potential to revolutionise the preparation of high concentration protein solutions from dry powders and make delivery faster and safer. The Company’s technology enables protein-based drugs to be formulated, manufactured and given to patients more efficiently and effectively such as via an inhaler rather than by injection. CentuRecon can be applied to multiple samples simultaneously, and is intended to significantly reduce the time spent by R&D scientists and healthcare professionals on the drug reconstitution process. The Company believed that medical practitioners will find CentuRecon straightforward and cost-effective to implement with patients benefiting from fewer injections and shorter clinical visits.
IP ASSETS FOR SALE:
- Rights in the XtalBio patent portfolio
- The XtalBio and CentuRecon brands which have achieved recognition within the industry
- Unregistered trade marks behind the XtalBio and CentuRecon brands